You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 133 No. 1, January 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  STUDIES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Intralesional Fluorouracil/Epinephrine Injectable Gel for Treatment of Condylomata Acuminata

A Phase 3 Clinical Study

James M. Swinehart, MD; Malcolm Sperling, MD; Stephen Phillips, MD; Stephen Kraus, MD; Stephen Gordon, MD; James M. McCarty, MD; Guy F. Webster, MD, PhD; Robert Skinner, MD; Andrew Korey, PhD; Elaine K. Orenberg, PhD

Arch Dermatol. 1997;133(1):67-73.


Abstract

Background and Design
A new intralesional sustained-release chemotherapy is under development as a treatment for condylomata acuminata; it is administered as an injectable gel that consists of fluorouracil and epinephrine with a purified bovine collagen as the gellant (fluorouracil/epinephrine gel). In this randomized, double-blind study, we evaluated the safety and efficacy of this intralesional treatment in 401 patients, using 2 active drug formulations (fluorouracil/epinephrine gel and fluorouracil gel alone) and a placebo. Each lesion was injected once a week for up to 6 weeks, and patients were followed up for 3 months.

Results
A total of 359 patients with 1926 condylomata underwent evaluation. For all lesions treated with fluorouracil/epinephrine gel, the complete response (CR) rate was 77%. For all patients treated with fluorouracil/ epinephrine gel, the CR rate was 61%. The fluorouracil/ epinephrine gel was significantly more effective (P<.002) in treating condylomata than the fluorouracil gel without epinephrine (CR rate, 43%); both were superior to placebo (CR rate, 5%). At 3 months after completion of treatment, recurrence rates in patients with CRs were as follows: fluorouracil/epinephrine gel group, 50%; fluorouracil gel group, 58%. No clinically significant drugrelated systemic reactions occurred. Finally, the type and severity of local tissue reactions of patients with a positive pretreatment collagen skin test result (6/401 [1.5%]) were similar to those of patients with a negative collagen skin test result.

Conclusion
The fluorouracil/epinephrine injectable gel is a safe and effective treatment for condylomata acuminata.

Arch Dermatol. 1997;133:67-73



Author Affiliations

From the Colorado Medical Research Center, Denver (Dr Swinehart); Future Healthcare Research Center, Altamonte Springs, Fla (Dr Phillips); Georgia Clinical Research Center Inc (Dr Kraus) and Crucible Group Inc (Dr Gordon), Atlanta, Ga; the Department of Dermatology, Thomas Jefferson University Medical College, Philadelphia, Pa (Dr Webster); the Department of Dermatology, University of Tennessee, Memphis (Dr Skinner); and Matrix Pharmaceutical Inc, Fremont, Calif (Drs Korey and Orenberg). Dr Sperling is in private practice in Fountain Valley, Calif, and Dr McCarty is in private practice in Fresno, Calif.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intralesional Fluorouracil/Epinephrine Gel for Genital Warts ...
Journal Watch Dermatology 1997;1997:5-5.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.